ECT2
Reactivity: Human
IHC (p)
Host: Rabbit
Polyclonal
unconjugated
Application Notes
ELISA: 1/10,000 - 1/40,000. Western Blot: 1/1,000 - 1/4,000. Immunoprecipitation. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
1.31 mg/mL (by UV absorbance at 280 nm)
Buffer
0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2 containing 0.01 % (w/v) Sodium Azide
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
ECT2, also known as epithelial cell transforming sequence 2 oncogene, was originally isolated as a transforming gene from epithelial cells. ECT2 catalyzes guanine nucleotide exchange on the small GTPases, RhoA, Rac1, and Cdc42. ECT2 may be phosphorylated during G2 and M phases, and phosphorylation may be required for its exchange activity. Unlike other known guanine nucleotide exchange factors for Rho GTPases, ECT2 exhibits nuclear localization in interphase, spreads throughout the cytoplasm in prometaphase, and is condensed in the midbody during cytokinesis. Expression of dominant-negative ECT2 or microinjection of affinity-purified anti-ECT2 antibody into interphase cells strongly inhibits cytokinesis. These results suggest that ECT2 is an important link between the cell cycle machinery and Rho signaling pathways involved in the regulation of cell division. Phosphorylation at T790 or S375 significantly affects the catalytic activity of ECT2.Synonyms: Epithelial cell-transforming sequence 2 oncogene